SURAKSHA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Suraksha Diagnostic Collaborates With United Imaging Technologies
June 18 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
SURAKSHA DIAGNOSTIC - COLLABORATION WITH UNITED IMAGING TECHNOLOGIES
SURAKSHA DIAGNOSTIC - TO ESTABLISH OVER 20 NEW IMAGING CENTRES; TO INVEST 2 BILLION RUPEES
Source text: [ID:]
Further company coverage: SURK.NS
(([email protected];))
June 18 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
SURAKSHA DIAGNOSTIC - COLLABORATION WITH UNITED IMAGING TECHNOLOGIES
SURAKSHA DIAGNOSTIC - TO ESTABLISH OVER 20 NEW IMAGING CENTRES; TO INVEST 2 BILLION RUPEES
Source text: [ID:]
Further company coverage: SURK.NS
(([email protected];))
Suraksha Diagnostic Completes Acquisition In Fetomat Wellness
April 9 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
COMPLETES ACQUISITION IN FETOMAT WELLNESS
Source text: ID:nBSELR4fm
Further company coverage: SURK.NS
(([email protected];;))
April 9 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
COMPLETES ACQUISITION IN FETOMAT WELLNESS
Source text: ID:nBSELR4fm
Further company coverage: SURK.NS
(([email protected];;))
Suraksha Diagnostic Approves Strategic Investment Of 51.9 Million Rupees In Fetomat
March 27 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
SURAKSHA DIAGNOSTIC LTD - APPROVES STRATEGIC INVESTMENT OF 51.9 MILLION RUPEES IN FETOMAT
SURAKSHA DIAGNOSTIC LTD - COMPANY TO HOLD 63% EQUITY IN FETOMAT POST-ACQUISITION
Source text: ID:nBSE4RkvtX
Further company coverage: SURK.NS
(([email protected];;))
March 27 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
SURAKSHA DIAGNOSTIC LTD - APPROVES STRATEGIC INVESTMENT OF 51.9 MILLION RUPEES IN FETOMAT
SURAKSHA DIAGNOSTIC LTD - COMPANY TO HOLD 63% EQUITY IN FETOMAT POST-ACQUISITION
Source text: ID:nBSE4RkvtX
Further company coverage: SURK.NS
(([email protected];;))
Suraksha Diagnostic Incorporates Subsidiary Suraksha Advanced Radiology
Jan 22 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
INCORPORATES SUBSIDIARY SURAKSHA ADVANCED RADIOLOGY
Source text: ID:nBSE8DHdmy
Further company coverage: SURK.NS
(([email protected];;))
Jan 22 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
INCORPORATES SUBSIDIARY SURAKSHA ADVANCED RADIOLOGY
Source text: ID:nBSE8DHdmy
Further company coverage: SURK.NS
(([email protected];;))
Suraksha Diagnostic Approves Formation Of Spv With Suraksha Diagnostic & Eye Centre
Dec 20 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
SURAKSHA DIAGNOSTIC - APPROVES FORMATION OF SPV WITH SURAKSHA DIAGNOSTIC & EYE CENTRE
SURAKSHA DIAGNOSTIC - SPV TO ESTABLISH 1.5 TESLA MRI CENTRE AT KOLKATA MEDICAL COLLEGE
Source text: ID:nNSE2Gr2L
Further company coverage: SURK.NS
(([email protected];))
Dec 20 (Reuters) - Suraksha Diagnostic Ltd SURK.NS:
SURAKSHA DIAGNOSTIC - APPROVES FORMATION OF SPV WITH SURAKSHA DIAGNOSTIC & EYE CENTRE
SURAKSHA DIAGNOSTIC - SPV TO ESTABLISH 1.5 TESLA MRI CENTRE AT KOLKATA MEDICAL COLLEGE
Source text: ID:nNSE2Gr2L
Further company coverage: SURK.NS
(([email protected];))
Events:
Lockin Period Expiry (Non-Promoter)
Lockin Period Expiry (Anchor)
Lockin Period Expiry (Anchor)
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Suraksha Diagnostic do?
Suraksha Diagnostic offers one-stop integrated solutions for pathology and radiology testing and medical consultation services including X-rays, ultrasonography, computerized tomography, magnetic resonance imaging scans and vaccination services. In addition to integrated pathology and radiology testing services, it also offers omnichannel medical consultation services via online and offline modes to its customers.
Who are the competitors of Suraksha Diagnostic?
Suraksha Diagnostic major competitors are Dr. Lal Pathlabs, Metropolis Health., Thyrocare Tech., Vijaya Diagnostic. Market Cap of Suraksha Diagnostic is ₹1,490 Crs. While the median market cap of its peers are ₹9,789 Crs.
Is Suraksha Diagnostic financially stable compared to its competitors?
Suraksha Diagnostic seems to be less financially stable compared to its competitors. Altman Z score of Suraksha Diagnostic is 9.43 and is ranked 4 out of its 5 competitors.
Does Suraksha Diagnostic pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Suraksha Diagnostic latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Suraksha Diagnostic allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Suraksha Diagnostic balance sheet?
Balance sheet of Suraksha Diagnostic is strong. But short term working capital might become an issue for this company.
Is the profitablity of Suraksha Diagnostic improving?
Yes, profit is increasing. The profit of Suraksha Diagnostic is ₹32.41 Crs for TTM, ₹31.82 Crs for Mar 2025 and ₹23.63 Crs for Mar 2024.
Is the debt of Suraksha Diagnostic increasing or decreasing?
The net debt of Suraksha Diagnostic is decreasing. Latest net debt of Suraksha Diagnostic is -₹40.9 Crs as of Sep-25. This is less than Mar-25 when it was -₹33.55 Crs.
Is Suraksha Diagnostic stock expensive?
Suraksha Diagnostic is not expensive. Latest PE of Suraksha Diagnostic is 45.2, while 3 year average PE is 57.75. Also latest EV/EBITDA of Suraksha Diagnostic is 16.23 while 3yr average is 19.63.
Has the share price of Suraksha Diagnostic grown faster than its competition?
Suraksha Diagnostic has given lower returns compared to its competitors. Suraksha Diagnostic has grown at ~-18.64% over the last 1yrs while peers have grown at a median rate of 5.0%
Is the promoter bullish about Suraksha Diagnostic?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 49.0% and last quarter promoter holding is 48.98%.
Are mutual funds buying/selling Suraksha Diagnostic?
The mutual fund holding of Suraksha Diagnostic is stable. The current mutual fund holding in Suraksha Diagnostic is 19.45% while previous quarter holding is 19.45%.
